<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574676</url>
  </required_header>
  <id_info>
    <org_study_id>CO-083252</org_study_id>
    <nct_id>NCT02574676</nct_id>
  </id_info>
  <brief_title>Quality of Life (QOL) Registry for Patients With AL Amyloidosis</brief_title>
  <official_title>Prospective Observational Study Measuring the Short-Form36 ( SF-36v2) and Other QOL Tools in an AL Amyloidosis Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prothena Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amyloidosis Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amyloidosis Support Groups</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amyloidosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quality Metrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prothena Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an online registry to document the psychometric properties of SF-36v2 among patients
      with AL Amyloidosis, to document patients' burden of disease, to better understand the
      patient's experience and to follow quality of life issues using a variety of QOL measures.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Psychometric evaluation of short-form 36 (SF-36v2) in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculate burden of illness from participants using SF-36 Mental Component Score (MCS) and Physical Component Score (PCS) compared with sample from US general population and three other chronic conditions: Congestive Heart Failure, Lymphoma and COPD</measure>
    <time_frame>Baseline- cross sectional</time_frame>
    <description>The comparison is made to other populations from the baseline cross-sectional measurements. There is no timeframe, except baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pathway to diagnosis and treatment through a disease history specific questionnaire collecting organ involvement, initial symptoms, diagnosis duration, treatment received and other disease characteristics</measure>
    <time_frame>Baseline- cross sectional</time_frame>
    <description>The analysis is done atbaseline .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of Kansas City Cardiomyopathy Questionnaire (KCCQ-12) in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of Patient Global Impression-Severity Scale (PGI-S) in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of Patient Global Assessment of Functioning (GAF) Scale in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of Hematology Patient Reported Symptom Screen (HPRSS) in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of Work Productivity and Activity Questionnaire: Specific Health Problem V2.0 (WPAI:SHP) in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric evaluation of MOS 6-Item Sleep Scale Standard in patients with AL Amyloidosis</measure>
    <time_frame>Change from Baseline to 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">343</enrollment>
  <condition>AL Amyloidosis</condition>
  <condition>Amyloidosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Al Amyloidosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have AL Amyloidosis

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Online registry</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

